Catalent, Ennaid Therapeutics collaborate to develop antiviral treatment for Covid-19 disease

This article was originally published here

As per terms of the deal, Catalent will involve in the development of a powder-in-capsule formulation for Ennaid’s ENU200 programme. Ennaid’s ENU200 is a patent-pending and repurposed oral

The post Catalent, Ennaid Therapeutics collaborate to develop antiviral treatment for Covid-19 disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply